High expression of CD73 as a poor prognostic biomarker in human colorectal cancer
High expression of CD73 as a poor prognostic biomarker in human colorectal cancer
复制标题
CD73 的高表达作为人类结直肠癌的不良预后生物标志物。
DOI：
10.1002/jso.23056
复制
发表时间：
2012-08-01
影响因子：
2.5
通讯作者：
Lan, Ping
中科院分区：
文献类型：
--
作者：
Wu, Xian-Rui;He, Xiao-Sheng;Lan, Ping
背景与目的探讨CD73在结直肠癌中的表达动态及其预后意义。方法采用Western blotting方法检测CD73的表达动态。用免疫组织化学方法检测CD73在两个独立队列的大肠癌组织中的表达。用X-Tile软件确定CD73表达的最佳切点。结果Western blotting分析显示CD73在结直肠癌组织中的表达明显高于正常大肠组织。根据X-Tile程序，确定CD73表达指数大于5.9的结直肠癌高表达的分界点。CD73在训练组和验证组的高表达分别为44.8%和50.4%。CD73的过表达与肿瘤分化程度、有无淋巴结转移、美国癌症分期联合委员会评分显著相关。CD73高表达患者的总体生存率低于CD73低表达患者。在多因素COX回归分析中，CD73的过度表达被证明是判断结直肠癌预后的独立生物标志物。结论CD73的高表达可作为判断结直肠癌患者预后的独立指标。J·奥科尔外科医生。2012年；106%：130137。(C)2012年威利期刊公司。
Background and Objectives To investigate the expression dynamics of CD73 and its prognostic significance in human colorectal cancer (CRC). Methods CD73 expression dynamics were detected by Western blotting. Immunohistochemistry was used to examine the expression of CD73 in CRC tissues from two independent cohorts by tissue microarrays. The optimal cutpoint of CD73 expression was assessed by the X-tile program. Results Western blotting analysis demonstrated that CD73 expression in CRC was significantly higher than in normal colorectal tissues. According to the X-tile program, the cutpoint for high expression of CD73 in CRC was determined when CD73 expression index was more than 5.9. High expression of CD73 was observed in 44.8% and 50.4% of CRC in the training and validation cohorts, respectively. Overexpression of CD73 was significantly correlated with tumor differentiation, nodal status, American Joint Committee on Cancer stage. Patients with high expression of CD73 had a poorer overall survival rate compared with patients with low expression of CD73 in both cohorts. In multivariate Cox regression analysis, overexpression of CD73 was proven to be an independent prognostic biomarker for CRC. Conclusions High expression of CD73 can be an independent and useful biomarker for predicting the poor survival of patients with CRC. J. Surg. Oncol. 2012; 106:130137. (c) 2012 Wiley Periodicals, Inc.